Home › Drievoudig negatieve borstkanker › North Carolina › Durham
Drievoudig negatieve borstkanker klinische studies in Durham, NC
12 studies voor Drievoudig negatieve borstkanker zoeken deelnemers op locaties in en rond Durham (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekruterenFase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mijl verwijderd
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruterenFase 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mijl verwijderd
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RekruterenFase 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruterenFase 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RekruterenFase 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
RekruterenFase 1
- University of North Carolina, Chapel Hill · 10 mijl verwijderd
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruterenFase 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RekruterenFase 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mijl verwijderd
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
RekruterenFase 2
- University of North Carolina, Chapel Hill · 10 mijl verwijderd
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
RekruterenFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mijl verwijderd
A Study of NX-1607 in Adults With Advanced Malignancies
RekruterenFase 1
- University of North Carolina, Chapel Hill · 10 mijl verwijderd
Drievoudig negatieve borstkanker studies in andere steden
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Andere studies in Durham
- Borstkanker64 studies
- Kanker (alle vormen)58 studies
- Niet-kleincellige longkanker39 studies
- Multipel myeloom37 studies
- Acute myeloïde leukemie33 studies
- Metastatische kanker33 studies
- Prostaatkanker32 studies
- Longkanker32 studies
- Colorectale kanker28 studies
- Eierstokkanker27 studies
- Chronische lymfatische leukemie27 studies
- Hartfalen26 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.